231 related articles for article (PubMed ID: 22064602)
1. The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer.
Sharifi N
J Investig Med; 2012 Feb; 60(2):504-7. PubMed ID: 22064602
[TBL] [Abstract][Full Text] [Related]
2. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.
Chang KH; Li R; Papari-Zareei M; Watumull L; Zhao YD; Auchus RJ; Sharifi N
Proc Natl Acad Sci U S A; 2011 Aug; 108(33):13728-33. PubMed ID: 21795608
[TBL] [Abstract][Full Text] [Related]
3. Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer.
Campbell TJ; Tindall DJ; Figg WD
Cancer Biol Ther; 2012 Mar; 13(5):237-8. PubMed ID: 22336886
[TBL] [Abstract][Full Text] [Related]
4. Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC
du Toit T; Bloem LM; Quanson JL; Ehlers R; Serafin AM; Swart AC
J Steroid Biochem Mol Biol; 2017 Feb; 166():54-67. PubMed ID: 27345701
[TBL] [Abstract][Full Text] [Related]
5. Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues.
Dai C; Chung YM; Kovac E; Zhu Z; Li J; Magi-Galluzzi C; Stephenson AJ; Klein EA; Sharifi N
Clin Cancer Res; 2017 Oct; 23(20):6351-6362. PubMed ID: 28733443
[No Abstract] [Full Text] [Related]
6. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.
Li R; Evaul K; Sharma KK; Chang KH; Yoshimoto J; Liu J; Auchus RJ; Sharifi N
Clin Cancer Res; 2012 Jul; 18(13):3571-9. PubMed ID: 22753664
[TBL] [Abstract][Full Text] [Related]
8. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
Mostaghel EA; Marck BT; Plymate SR; Vessella RL; Balk S; Matsumoto AM; Nelson PS; Montgomery RB
Clin Cancer Res; 2011 Sep; 17(18):5913-25. PubMed ID: 21807635
[TBL] [Abstract][Full Text] [Related]
9. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.
Li Z; Bishop AC; Alyamani M; Garcia JA; Dreicer R; Bunch D; Liu J; Upadhyay SK; Auchus RJ; Sharifi N
Nature; 2015 Jul; 523(7560):347-51. PubMed ID: 26030522
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
[TBL] [Abstract][Full Text] [Related]
11. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
12. Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level.
Rouleau M; Neveu B; Caron P; Morin F; Toren P; Lacombe L; Turcotte V; Lévesque É; Guillemette C; Pouliot F
J Urol; 2022 Dec; 208(6):1214-1225. PubMed ID: 36102111
[TBL] [Abstract][Full Text] [Related]
13. 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?
Storbeck KH; Bloem LM; Africander D; Schloms L; Swart P; Swart AC
Mol Cell Endocrinol; 2013 Sep; 377(1-2):135-46. PubMed ID: 23856005
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of the 5α-androstanedione pathway for castration-resistant prostate cancer.
Sharifi N
Future Oncol; 2011 Nov; 7(11):1239-41. PubMed ID: 22044197
[No Abstract] [Full Text] [Related]
15. Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.
Montgomery B; Nelson PS; Vessella R; Kalhorn T; Hess D; Corey E
BMC Cancer; 2010 May; 10():244. PubMed ID: 20509933
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer androgen biosynthesis relies solely on CYP17A1 downstream metabolites.
Snaterse G; Taylor AE; Moll JM; O'Neil DM; Teubel WJ; van Weerden WM; Arlt W; Hofland J
J Steroid Biochem Mol Biol; 2024 Feb; 236():106446. PubMed ID: 38104728
[TBL] [Abstract][Full Text] [Related]
17. 11β-hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5α-reductase yielding 11β-hydroxy-5α-androstanedione.
Swart AC; Schloms L; Storbeck KH; Bloem LM; Toit Td; Quanson JL; Rainey WE; Swart P
J Steroid Biochem Mol Biol; 2013 Nov; 138():132-42. PubMed ID: 23685396
[TBL] [Abstract][Full Text] [Related]
18. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH
Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173
[TBL] [Abstract][Full Text] [Related]
19. 5alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3.
Negri-Cesi P; Colciago A; Poletti A; Motta M
Prostate; 1999 Dec; 41(4):224-32. PubMed ID: 10544295
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
Rehman Y; Rosenberg JE
Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
